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The occurrence of toxic drug residues is a hot topic concerning emerging environmental contaminants. 
The occupational exposure to anticancer drugs could be severe for health-care personnel and general 
public attending potentially polluted areas (such as oncology departments of hospitals) because of 
high therapeutic concentrations. The aim of this work was to generate degradation compounds similar 
to those formed in metabolic or environmental pathways by adopting a photocatalytic process and to 
identify them in indoor environments alongside parent compounds. A photodegradation model was 
applied to cyclophosphamide and mitomycin C. Studied substances and degradants were quantified 
in environmental samples by liquid chromatography with multiple-stage mass spectrometry (LC–MSn) 
analysis using an orbital trap instrument with an electrospray interface. Various oxidative degradants 
were formed using the photocatalytic simulation model of degradation of antineoplastic drugs, beside 
some hydrolysis and molecule breakdown subproducts. High resolution MSn spectra were used to 
identify and confirm the proposed structures. Kinetics of formation of the main degradation products 
were also studied.
LC–HRMS Determination of 
Anticancer Drugs as Occupational 
Contaminants Applied to 
Photocatalytic Degradation of 
Molecules of Different Stability
T
he frequency of recognition of toxic drug residues is an 
important issue concerning emerging environmental 
contaminants. This problem is also exacerbated by the 
low therapeutic index of drugs used in cancer chemotherapy. 
The occupational exposure to residues of anticancer drugs 
must be kept under strict control by safety managers because 
it could be severe for health care personnel and general public 
attending potentially polluted areas (such as oncology depart-
ments and pharmacies of hospitals) because of high therapeu-
tic concentrations. In addition, urinary elimination by patients 
represents a source of contamination. The monitoring of drug 
residues is necessary to guarantee occupational safety and the 
absence of pollution. The presence of anticancer drug resi-
dues in environmental water samples has been reported (1–3). 
Looking closer at the structural features of these compounds, 
it is possible to see that the majority of chemotherapeutic drugs 
hold molecular structures with a high chemical reactivity (4). 
As a consequence of this great aptitude to undergo chemical 
transformation, it could be difficult to record measurable lev-
els of some of these drugs. As an example, in a previous study 
(5) we found evidence of the difficulty to recover traces of mi-
tomycin C because of its low stability. The aim of this work is 
to generate degradation compounds similar to those formed 
in metabolic or environmental pathways by adopting a pho-
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tocatalytic process and to identify them 
in indoor environments. An additional 
purpose of this study is to develop a se-
lective and sensitive method as a tool to 
detect drug transformation and degra-
dation products and to quantify them in 
biological and environmental samples, 
beside parent compounds.
In t h is  work,  t wo a nt ica ncer 
drugs were studied: the N-mustard 
c yc lophospha m ide  (N ,N -bi s (2-
chloroethyl)-1,3,2-oxazaphosphinan-
2-amine 2-oxide) and the aziridine 
mitomycin C ([(1aS,8S,8aR,8bS)-6-
amino-8a-methoxy-5-methyl-4,7-di-
oxo-1,1a,2,4,7,8,8a,8b-octahydroazi-
reno[2′,3′:3,4]pyrrolo[1,2-a]indol-8-yl]
methyl carbamate). We chose cyclo-
phosphamide and mitomycin C be-
cause of the popular use of these drugs 
and because of their different stability. 
The photodecomposition of drugs was 
carried out by heterogeneous photo-
catalysis, using titanium dioxide in 
water as previously reported (6,7). By 
this process, the photodecomposition of 
drugs could be due to either oxidative 
species or reductive conduction band 
electrons (8,9).
A highly sensitive method was de-
veloped to measure the degradation 
products in wipe samples that allows 
detection of parent drugs at the nano-
gram level (5). Occupational exposure 
monitoring of these drugs shows fre-
quent cyclophosphamide positive mea-
surements but no significant mitomycin 
C determination. The high instability 
of the mitomycin molecule is probably 
the main cause of these findings. One 
of the targets of this work is to identify 
new possible markers of mitomycin in 
environmental pollution. Identification 
and characterization of degradation 
compounds could contribute signifi-
cantly to the development of more ef-
fective analytical methods to monitor 
occupational exposure. 
High performance liquid chroma-
tography (HPLC) coupled to mass 
spectrometry (MS) via an electrospray 
ionization (ESI) interface is a powerful 
tool to identify and measure anticancer 
drugs in the environment (10), especially 
in health care settings (11). However, liq-
uid chromatography—mass spectrom-
etry (LC–MS) analysis performed in 
full-scan mode is not sensitive enough 
to detect and characterize metabolites at 
trace levels and the excellent sensitivity 
provided in multiple reaction monitor-
ing (MRM) mode suffers from a lack of 
structural information to characterize 
the huge number of potential degradants 
formed from drug compounds.
For this reason, we developed a sensi-
tive liquid chromatography–high-reso-
lution mass spectrometry (LC–HRMS) 
methodology using orbital trap tech-
nology (12) with the purpose of exploit-
ing the potential of untargeted analysis 
for which it is fitted. From the analysis 
of spectra acquired at high resolving 
power, it was possible to hypothesize 
the structure of the main degradation 
products observed in the photocatalysis 
simulation model.
Experimental
Chemicals and Materials 
LC–MS-grade acetonitrile was pur-
chased from VWR (VWR Interna-
tional PBI). Extra-pure formic acid was 
purchased from Fluka (Sigma-Adrich). 
Cyclophosphamide was from Baxter and 
Figure 1: Cyclophosphamide MH+ MS2 proposed fragmentation pathways.
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mitomycin C was purchased from ProS-
trakan. Experiments were carried out 
using TiO2 Degussa P25 as the photo-
catalyst. Methanol, trichloroacetic acid, 
heptafluorobutanoic acid, and ammonia 
were purchased from Sigma-Aldrich at a 
Table I: Parent drugs, degradation compounds, and LC–HRMSn parameters
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2 MS3
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purity ≥99%. HPLC-grade water was ob-
tained using a MilliQ System Academic 
system (Millipore).
Irradiation Technique
Irradiation was performed using a 
Philips TLK/05 lamp (40 W/m2) with 
maximum emission at 360 nm. Irradia-
tion experiments were carried out in 
Pyrex glass cells containing the studied 
drug (20 mg/L) and titanium dioxide 
(200 mg/L) in ultrapure water. The 
temperature reached during irradia-
tion was 38 ± 2 °C. 
Liquid Chromatography 
Chromatographic separation followed 
by MS analysis was run on a 150 × 2.0 
mm, 3-µm dp Phenomenex Luna C18 
column preceded by a Luna C18 guard 
column, using a Dionex Ultimate 3000 
HPLC instrument (Thermo Fisher 
Figure 3: Plots of the kinetics of (a) parent compound decrease and (b) formation of main cyclophosphamide transformation products (TPs).
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Figure 4: LC–ESI HRMSn chromatograms of MC-5, MC-6, and MC-7 degradation products (after 5 min of irradiation) together with hypothesized 
fragmentation pathways that are able to justify the main MS3 (for isomers MC-5 and MC-6) and MS2 fragments.
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Scientific). The injection volume was 
20 μL and the flow rate was 200 μL/min. 
Mobile-phase A was 0.1% formic acid in 
water, and mobile-phase B was acetoni-
trile. After a 2-min isocratic run at 5% 
B, a gradient to 100% B was concluded 
at 20 min. A column wash with 100% B 
(3 min) was followed by equilibration 
with 5% B starting at 25 min and main-
tained until 30 min. All injection vol-
umes were 20 μL, the column tempera-
ture was 30 °C, and the f low rate was 
0.2 mL/min. The wash solvent was 1:2 
(v/v) water–acetonitrile. 
High-Resolution Mass Spectrometry 
An LTQ Orbitrap mass spectrometer 
(Thermo Scientific), equipped with 
an atmospheric pressure interface and 
an ESI ion source, was used. Analyses 
were carried out in both the positive 
and negative ion modes. The LC col-
umn eff luent was delivered to the ion 
source using nitrogen as both sheath 
and auxiliary gas. The source volt-
age was set to 4.4 kV (-4.0 kV in the 
negative ion mode). The heated capil-
lary temperature was maintained at 
275 °C. The nitrogen f lows as sheath 
gas and auxiliary gas were set at 20 
and 10 (arbitrary units), respectively. 
The acquisition method used had pre-
viously been optimized in the tuning 
sections for the parent compound 
(capillary, magnetic lenses, and colli-
mating octapoles voltages) to achieve 
maximum sensitivity. The main tun-
ing parameters adopted for the ESI 
source in the positive ion mode were 
24 V for capillary voltage and 65 V 
for tube lens and -15 V and -54 V in 
the negative ion mode, respectively. 
Full scan spectra were acquired in the 
range 50–1000 m/z. Multiple-stage 
mass spectrometry (MSn) spectra 
were acquired in the range between 
ion trap cut-off and precursor ion 
m/z values. Spectra were acquired 
with the resolution R = 30000 (full 
width at half maximum [FWHM]). 
Mass accuracy of recorded ions (vs. 
calculated) was ± 0.001 u (without in-
ternal calibration). Calibration curves 
for cyclophosphamide and mitomycin 
C were constructed from five calibra-
tion points for each compound in the 
range 0.10–50.0 μg/mL. 
Figure 5: LC–HRMS chromatogram of the cyclophosphamide photocatalytic degradation mixture 
after 15 min of irradiation (positive ion mode; on the top) and 30 min of irradiation (negative ion 
mode; on the bottom).
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Results and Discussion
Cyclophosphamide and 
Mitomycin C MS-MS Study 
The MS2 and MS3 fragmentation study 
of the studied compounds showed 
some characteristic losses that were 
considered in identifying the un-
known compounds formed during 
the photo-induced degradation of the 
drugs. The product ions generated 
from protonated molecular ions are 
shown in Figures 1 and 2. MSn frag-
ment identification was confirmed by 
the high resolution study of neutral 
losses. The main product ions of cy-
clophosphamide were formed through 
an ethylene molecule loss or three 
different phosphoric ring breakings 
respectively leading to the formation 
of aziridine (106.0423 m/z), amine 
(142.0182 m/z), or imine (140.0034 
m/z) nitrogen mustard structures. The 
successive fragmentation of these ions 
mainly involve simple HCl elimination 
(Figure 1). 
The protonated ion of mitomycin C 
generates a single product ion (242.0930 
m/z) by concerted loss of methanol and 
carbamic acid. The main MS3 losses in-
volve CO, HCN, and ammonia elimi-
nation (Figure 2). The MS4 converg-
ing losses of CO and NH3 to give the 
common product ion at 197.0708 m/z 
is noteworthy.
In the negative ion mode, cyclophos-
phamide does not ionize in a noticeable 
way, whereas mitomycin C originates 
at a [M-H]– ion, about 10 times less in-
tense than the corresponding MH+ ion 
formed in the positive ion mode. This 
deprotonated ion, by MS-MS fragmen-
tation, again gives a single product ion 
eliminating HCNO (43.0073 u).
Laboratory Simulation 
Laboratory simulation was initially 
performed on cyclophosphamide and 
mitomicyn C in ultrapure water, in the 
presence of titanium dioxide as photo-
catalyst. The parent drugs were easily 
degraded and completely disappeared 
within 30 min of irradiation (Figure 
3a). In parallel with the disappearance 
of parent drugs, a number of transfor-
mation products were identified. Their 
sequential evolution is shown for cy-
clophosphamide in Figure 3b and will 
Figure 6: Cyclophosphamide degradation products detected after heterogeneous photocatalysis 
decomposition.
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Figure 7: MS2 spectrum of degradation product CP-1 together with the hypothesized 
fragmentation pathway.
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be discussed in the characterization of 
transformation products section. Trans-
formation products were characterized 
by different m/z ratios of the precursor 
ions as well as by MS3 analysis in the 
case of hydroxylated isomers, as shown 
in Figure 4. This finding is in agreement 
with the nonselectivity of the active spe-
cies involved in the photocatalytic pro-
cess, that is, OH radicals (13).
Several species have been detected 
along with the cyclophosphamide and 
mitomycin C disappearance. The inter-
mediates were characterized by taking 
into account their chromatographic be-
havior and kinetics of evolution, coupled 
with the exact mass information, an ac-
curate analysis of MS and MSn spectra 
and a comparison with parent drug frag-
mentation pathways. Retention times, 
m/z values, and elemental composition 
of HRMSn observed ions are reported 
in Table I.
Characterization of 
Cyclophosphamide Transformation 
Products from Irradiation Study 
Six main species were detected within 
cyclophosphamide degradation. Ex-
tracted chromatograms at 2 ppm mass 
tolerance level are shown in Figure 5. 
We evaluated both the formation of 
known metabolites and the generation 
of new unknown photocatalytic deg-
radation products. The isotopic abun-
dance pattern was used as a powerful 
additional constraint for identification 
of unknowns. 
The cyclophosphamide degradation 
study showed both the formation of 
previously known human metabolites 
(14,15) (CP-1, CP-2, and CP-3 shown 
in Figure 6) and the generation of 
three new degradants whose potential 
structures were reported in Figure 6 
(CP-4, CP-5, and CP-6). Compound 
CP-1 matches with the main known 
metabolite 4-ketocyclophosphamide 
whereas the quantitatively most abun-
dant compound on the bases of peak 
areas obtained was the compound 
CP-3, known as NOR-nitrogen mus-
tard. The maximum survival time in 
the presence of titanium dioxide and 
light was 240 min (appearance and 
disappearance kinetics are shown in 
Figure 3). For example, MS2 spectrum 
(CP-1) is shown in Figure 7. In this 
study, the acquisition of positive and 
negative ions spectra was crucial be-
cause CP-2 and CP-3 were detectable 
as positive ion only when CP-4, CP-5, 
and CP-6 negative ions.
Figure 8: Mitomycin C degradation products detected after heterogeneous photocatalysis 
decomposition (bottom box) in comparison with the known metabolites (16) (top box).
O
O
O
O
N
H
2
N
NH
2
NH
MC
H
3
C
OCH
3
O
O
O
O
N
H
2
N
NH
2
NH
2
MC-1
H
3
C
O
OH
O
O
O
N
H
2
N
NH
2
OCH
3 OCH3
OHC
NH
MC-5
MC-6
H
3
C
O
OH
O
O
O
O
N
H
2
N
NH
2
NHH
3
C
MC-7
O
O
O
O
N
H
2
N
NH
2
NH
O
O
OH
O
O
N
H
2
N
NH
2
NH
2
MC-2 (cis)
MC-3 (trans)
H
3
C
O
O
O
OH
N
H
2
N
NH
2
NH
MC-4
H
3
C
Known human metabolites / degradants
Main photocatalysis products
Figure 9: HRMS3 spectra of isomeric compounds MC-5 and MC-6.
100
90
80
70
60
50
40
30
20
10
0
R
e
la
t
iv
e
 a
b
u
n
d
a
n
c
e
100
90
80
70
60
50
40
30
20
10
0
R
e
la
t
iv
e
 a
b
u
n
d
a
n
c
e
MC-5
MC-6
HCOOH loss
H
2
O loss
C
2
H
5
N loss
CH
3
OH loss
244.1086
272.1037
273.0875
229.0976
247.0718
273.0875
165.0658
NH
3
 loss
NH
3
 loss
100 200 300150 250 350
m/z
www.spec t roscopyonl ine .com May 2013   Current Trends in Mass Spectrometry  37
Characterization of 
Mitomycin C Transformation 
Products from Irradiation Study 
The degradation pattern of mitomycin 
C looks simpler than the cyclophospha-
mide one. Three species were recognized 
and their chromatograms are shown in 
Figure 4.
The mitomycin C degradation study 
did not show any appreciable trace of 
known degradants. The formation of 
such transformation products, named 
mitosanes and mitosenes, is well known 
in the literature (16,17) (MC-1, MC-2, 
MC-3, and MC-4, Figure 8). On the 
contrary, three new compounds were 
obtained by heterogeneous photoca-
talysis (MC-5, MC-6, and MC-7; Figure 
8).  The first two products are formed by 
hydroxylation and are isomers; the last 
one comes from a hydroxylation and 
oxidation process. To hypothesize the 
structures reported in Figure 4, besides 
the corresponding chromatograms, a 
high resolving power multistage MS 
study was performed. We hypothe-
sized the structures shown in Figure 2 
and Figure 4 for the couple of isomers 
named MC-5 and MC-6 because of the 
different MS3 fragmentation observed. 
The elimination of methanol that char-
acterizes MC-5 MS3 behavior suggested 
that we leave the methoxy moiety un-
modified and position the OH group 
on C-8 to explain the simple formamide 
loss. On the contrary, MC-6 was identi-
fied as 8a-hydroxymethoxy-derivative 
to justify the MS3 base peak formed by 
H2CO2 elimination. Also, in this case, 
we considered the more probable OH at-
tack on the methoxy group than on the 
5-methyl substituent because the MS2
behavior was different from the parent 
drug one. The two MS3 example spectra 
are displayed in Figure 9.
Conclusions
In a workplace environment, just like in 
vivo, exogenous compounds go through 
many chemical and bio-transforma-
tions; however, most of these transfor-
mations could not be detected by cur-
rent methods applied to metabolism 
studies or targeted on a specific drug 
molecule (18,19). In the present study, 
we demonstrated how low-abundance 
drug metabolites and unknown degra-
dation products could be successfully 
detected, analyzed, and characterized. 
Chemical structures of these detected 
metabolites were proposed, based on 
MS and MSn spectra. The described 
methodology was applied in heteroge-
neous photocatalysis experiments in 
which two anticancer drugs were ar-
tificially decomposed. The photocata-
lytic degradation model identified new 
transformation products from two an-
ticancer drugs, cyclophosphamide and 
mitomycin C. In the case of cyclophos-
phamide, the simulation model gives a 
broad scenario of the formation of de-
gradants including known human me-
tabolites. In contrast, the same model 
does not permit the formation of known 
degradation products of mitomycin C, 
formed both in vivo and in spontaneous 
decomposition, probably because of the 
very different reaction kinetics.
From the analytical point of view, 
LC–HRMS methodology can greatly 
help drug residue monitoring together 
with the untargeted analytes identifica-
tion, and, combined with photocataly-
sis, could be a suitable tool to simulate 
biological and chemical transformations 
through photochemical laboratory ex-
periments. This suggests that new struc-
tures for future metabolic and environ-
mental studies are possible.
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